Thyrocare Technologies
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Thyrocare Technologies is navigating a pivotal transition from a preventive diagnostics provider to a comprehensive diagnostics partner, as highlighted by management's focus on expanding its franchise network and specialty diagnostics offerings. The company's strategy to penetrate Tier 3/4 markets and divest underperforming segments is expected to enhance capital efficiency and drive revenue growth. Vista's forecast anticipates mid- to high-teen revenue growth, supported by a robust demand for specialty tests and a disciplined approach to capital allocation. While the healthcare sector is experiencing stable pricing power, Thyrocare faces headwinds from increased competition and potential pricing pressures. Over the next 12-24 months, key opportunities include the expansion of its franchise network and the introduction of new diagnostic services, while watchpoints include the performance of its imaging business and the impact of regulatory risks. Overall, Thyrocare's outlook remains positive, with expected upside of approximately 17% and a target price of INR 675.41, reflecting a fair valuation aligned with intrinsic value
Why We Like This Stock
- Management's strategic focus on expanding the franchise network and specialty diagnostics is expected to drive revenue growth
- The company's disciplined capital allocation and divestment of underperforming segments enhance operational efficiency
- Robust demand for high-margin specialty tests positions Thyrocare favorably in a growing healthcare market
Things To Watch Out For
- Increased competition from online diagnostics firms poses a risk to market share and pricing power
- Potential pricing pressures and regulatory risks could impact profitability and margins
- The underperformance of the imaging business may hinder overall growth if not addressed effectively
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 572 | 687 | 829 | 897 | 1,030 |
| Profit Before Tax (Cr.) | 97 | 137 | 219 | 234 | 273 |
| PBT Margin | 16.9% | 20.0% | 26.4% | 26.1% | 26.5% |
| Net Profit (Cr.) | 66 | 93 | 160 | 170 | 198 |
| Earnings Per Share | 4.2 | 5.9 | 10.0 | 10.7 | 12.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Elara Capital | ▲ Buy | 669 | 24-Jul-2026 |
| ICICI Securities | ▲ Buy | 650 | 24-Jul-2026 |
| BKSecurities | ▲ Buy | 615 | 22-Jun-2026 |
Company Overview
Show Company Profile
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.